

Ardea Biosciences, Inc./DE  
Form 8-K  
November 07, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 7, 2011

**Ardea Biosciences, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**1-33734**  
(Commission  
File Number)

**94-3200380**  
(IRS Employer  
Identification No.)

Edgar Filing: Ardea Biosciences, Inc./DE - Form 8-K

**4939 Directors Place**  
**San Diego, California**  
(Address of principal executive offices)  
**Registrant's telephone number, including area code: (858) 652-6500**

**92121**  
(Zip Code)

**Not applicable.**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure**

The Company has recently received and publicly announced certain clinical data related to its products. A copy of the press release announcing the data is filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety.

A copy of presentation materials describing the Company's business to be used by the Company at a scientific presentation and from time to time thereafter is filed as Exhibit 99.2 hereto. These materials reflect updates to information previously furnished by the Company regarding the Company's research and development programs. The Company does not intend to file any update of these presentation materials in the future. The fact that these updated presentation materials are being furnished should not be deemed an admission as to the materiality of any information contained in the materials.

The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:

<b>Exhibit Number</b>	<b>Document Description</b>
99.1	Press release dated November 7, 2011.
99.2	Ardea Biosciences, Inc. presentation materials dated as of November 7, 2011, and to be used from time to time thereafter.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ARDEA BIOSCIENCES, INC.**

Date: November 7, 2011

/s/ CHRISTIAN WAAGE  
Christian Waage  
General Counsel

**EXHIBIT LIST**

<b>Exhibit Number</b>	<b>Document Description</b>
99.1	Press release dated November 7, 2011.
99.2	Ardea Biosciences, Inc. presentation materials dated as of November 7, 2011, and to be used from time to time thereafter.